According to the Complaint, HP Inc. provides personal computers, printers, and related supplies, solutions, and services. The Company conducts business primarily through two segments: Printing and Personal Systems. The Printing segment provides consumer and commercial printer hardware, supplies, solutions, and services. The Personal Systems segment provides commercial and consumer computers and related software, support, and services.

According to the Complaint, Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the U.S. Intercept's lead product candidate is Ocaliva (OCA), a farnesoid X receptor agonist used for the treatment of PBC, a rare and chronic liver disease, in combination with ursodeoxycholic acid in adults. The Company is also developing OCA for various other indications, including NASH.

According to the Complaint, Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for cardiovascular diseases, including the Tiara technology and the Reducer. The Company’s Reducer is a medical device that treats refractory angina by altering blood flow in the heart’s circulatory system.

According to the Complaint, Raytheon Technologies Corporation purports to be an aerospace and defense company providing advanced systems and services for commercial, military, and government customers worldwide. On April 3, 2020, United Technologies Corporation and Raytheon Company completed a merger and changed the Company’s name to “Raytheon Technologies Corporation” and its common stock symbol to “RTX.” Before the merger in April 2020, Raytheon Company stock traded under the ticker symbol “RTN.”

According to the Complaint, Citigroup Inc. (“Citi”) is a multinational investment bank and financial services corporation.

According to the Complaint, Wells Fargo & Company is a financial services and bank holding company headquartered in San Francisco, California.

According to the Complaint, Celsion Corporation is an integrated development clinical stage oncology drug company that focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Celsion’s lead product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin that is in Phase III clinical development for treating primary liver cancer.

According to the Complaint, Zosano Pharma Corporation is a clinical stage pharmaceutical company. Its proprietary intracutaneous delivery system purports to offer rapid absorption of drug, consistent drug delivery, improved ease of use, and room-temperature stability. Its intracutaneous patch consists of an array of titanium microneedles that is coated with Zosano’s proprietary formulation of a previously approved drug that is attached to an adhesive patch. The patch purports to offer rapid and consistent delivery of the drug via the microneedles that penetrate the skin, resulting in dissolution and absorption of the drug.

According to the Complaint, Bayerische Motoren Werke Aktiengesellschaft ("BMW" or the "Company"), together with its subsidiaries, purports to develop, manufacture, and sell automobiles and motorcycles, and spare parts and accessories worldwide.

According to the Complaint, First American Financial Corp., through its subsidiaries, provides financial services through its title insurance and services segment and its specialty insurance segment.

According to the Complaint, JPMorgan Chase & Co. purports to operate as a financial services company worldwide. The Company operates in four segments: Consumer & Community Banking, Corporate & Investment Bank, Commercial Banking, and Asset & Wealth Management.

According to the Complaint, Innate Pharma S.A. purports to be a clinical-stage biotechnology company engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.

According to the Complaint, Las Vegas Sands Corp., together with its subsidiaries, develops, owns, and operates integrated resorts in Asia and the U.S. Its integrated resorts feature accommodations, gaming, entertainment and retail malls, convention and exhibition facilities, celebrity chef restaurants, and other amenities. Las Vegas Sands’ properties include, among others, the Marina Bay Sands resort in Singapore, which operates a casino.

According to the Complaint, Sunworks, Inc., through its subsidiaries, provides photovoltaic based power systems for the agricultural, commercial, industrial, public works, and residential markets in California, Massachusetts, Nevada, Oregon, New Jersey, and Washington.

According to the Complaint, Evolus, Inc. is a medical aesthetic company formed with the sole aim to develop and introduce a cheaper alternative to Botox® to the U.S. market.

According to the Complaint, Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc., and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. Among Reata’s drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich’s ataxia (“FA”). Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the FDA.

According to the Complaint, Turquoise Hill Resources Ltd. is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia, which is the Company's principal and only material resource property. Oyu Tolgoi is a combined open pit and underground mining project in the Khanbogd sum, or district, in Mongolia, located in the south Gobi Desert. The site was discovered in 2001 and is currently being developed as a joint venture between Turquoise Hill, which has a 66% ownership stake in the mine, and the Mongolian government, which has a 34% stake.

According to the Complaint, Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat cystic fibrosis.

According to the Complaint, Loop Industries, Inc. is a technology company that purports to own proprietary technology that depolymerizes no- and low-waste PET plastic and polyester fiber. The resulting material is used to create PET resin for food-grade packaging.

According to the Complaint, Mesoblast Limited develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcelL), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow.